Single-chain antibody fragment-based adsorbent for blood purification

C. Daniels; Guillermo Antonio Ameer

Single-chain antibody fragment-based adsorbent for blood purification

C. Daniels^*, Guillermo Antonio Ameer

^*Corresponding author for this work

Biomedical Engineering

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

Single-chain variable region (scFv) antibody fragments were used to remove β₂-microglobulin (β₂m) from the blood of patients. The variable heavy (Vh) and variable light (VI) chains of the anti human β₂ monoclonal antibody BBM. 1 were cloned via RT-PCR of the hybridoma cell line. The regeneration ability of the absorbents was tested by stripping the absorbed β_m with 0.05 M citrate buffer and repeating the binding capacity measurements. Results show the clinical application of this adsorbent can be economically feasible due the ability to regenerate the adsorption matrix multiple times without significant loss of binding activity.

Original language	English (US)
Title of host publication	Transactions - 7th World Biomaterials Congress
Number of pages	1
State	Published - Dec 1 2004
Event	Transactions - 7th World Biomaterials Congress - Sydney, Australia Duration: May 17 2004 → May 21 2004

Other

Other	Transactions - 7th World Biomaterials Congress
Country	Australia
City	Sydney
Period	5/17/04 → 5/21/04

ASJC Scopus subject areas

Engineering(all)

Access to Document

Fingerprint Dive into the research topics of 'Single-chain antibody fragment-based adsorbent for blood purification'. Together they form a unique fingerprint.

Cite this

Daniels, C., & Ameer, G. A. (2004). Single-chain antibody fragment-based adsorbent for blood purification. In Transactions - 7th World Biomaterials Congress

@inproceedings{92b57c5449514368938d00a7fb8be982,

title = "Single-chain antibody fragment-based adsorbent for blood purification",

abstract = "Single-chain variable region (scFv) antibody fragments were used to remove β2-microglobulin (β2m) from the blood of patients. The variable heavy (Vh) and variable light (VI) chains of the anti human β2 monoclonal antibody BBM. 1 were cloned via RT-PCR of the hybridoma cell line. The regeneration ability of the absorbents was tested by stripping the absorbed βm with 0.05 M citrate buffer and repeating the binding capacity measurements. Results show the clinical application of this adsorbent can be economically feasible due the ability to regenerate the adsorption matrix multiple times without significant loss of binding activity.",

author = "C. Daniels and Ameer, {Guillermo Antonio}",

year = "2004",

month = dec,

day = "1",

language = "English (US)",

isbn = "1877040193",

booktitle = "Transactions - 7th World Biomaterials Congress",

note = "Transactions - 7th World Biomaterials Congress ; Conference date: 17-05-2004 Through 21-05-2004",

}

TY - GEN

T1 - Single-chain antibody fragment-based adsorbent for blood purification

AU - Daniels, C.

AU - Ameer, Guillermo Antonio

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Single-chain variable region (scFv) antibody fragments were used to remove β2-microglobulin (β2m) from the blood of patients. The variable heavy (Vh) and variable light (VI) chains of the anti human β2 monoclonal antibody BBM. 1 were cloned via RT-PCR of the hybridoma cell line. The regeneration ability of the absorbents was tested by stripping the absorbed βm with 0.05 M citrate buffer and repeating the binding capacity measurements. Results show the clinical application of this adsorbent can be economically feasible due the ability to regenerate the adsorption matrix multiple times without significant loss of binding activity.

AB - Single-chain variable region (scFv) antibody fragments were used to remove β2-microglobulin (β2m) from the blood of patients. The variable heavy (Vh) and variable light (VI) chains of the anti human β2 monoclonal antibody BBM. 1 were cloned via RT-PCR of the hybridoma cell line. The regeneration ability of the absorbents was tested by stripping the absorbed βm with 0.05 M citrate buffer and repeating the binding capacity measurements. Results show the clinical application of this adsorbent can be economically feasible due the ability to regenerate the adsorption matrix multiple times without significant loss of binding activity.

UR - http://www.scopus.com/inward/record.url?scp=13844254398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844254398&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:13844254398

SN - 1877040193

SN - 9781877040191

BT - Transactions - 7th World Biomaterials Congress

T2 - Transactions - 7th World Biomaterials Congress

Y2 - 17 May 2004 through 21 May 2004

ER -